Outset Medical, Inc. ( (OM) ) has released its Q1 earnings. Here is a breakdown of the information Outset Medical, Inc. presented to its investors.
Outset Medical, Inc. is a medical technology company that has developed the Tablo Hemodialysis System, a unique solution aimed at simplifying and reducing the cost of dialysis treatments across various care settings.
In its latest earnings report for the first quarter of 2025, Outset Medical demonstrated significant growth in both console and recurring revenue streams, alongside an expansion in gross margins and a notable reduction in cash usage.
The company reported a 6% increase in net revenue to $29.8 million, with Tablo console revenue rising 23% from the previous quarter. Recurring revenue from Tablo consumables and services saw a 20% year-over-year increase, reaching $22.7 million. Gross margins improved to 37.2%, and non-GAAP gross margins reached 37.6%, marking a significant improvement from the previous year. Additionally, the company reduced its net cash used in operating activities by 44% compared to the same period last year.
Despite a net loss of $25.8 million, Outset Medical’s strategic focus on operational efficiency and cost reduction has set a clear path toward profitability. The company reiterated its revenue guidance for 2025, expecting to achieve between $115 million and $125 million, with non-GAAP gross margins in the high-30% range.
Looking ahead, Outset Medical remains committed to its strategic initiatives and operational improvements, positioning itself for continued growth and advancement in the dialysis market. The company’s management expressed confidence in its ability to capitalize on its unique market position and technological innovations to drive future success.